2. Cell Cycle/DNA Damage Epigenetics Apoptosis Protein Tyrosine Kinase/RTK Metabolic Enzyme/Protease
  3. HDAC Apoptosis Bcr-Abl HSP
  4. MRLB-223

MRLB-223 is a preferential HDAC1 and HDAC2 inhibitor with activity against tumor cells.MRLB-223 induces histone hyperacetylation, intrinsic apoptotic pathway activation, tumor cell apoptosis, Hsp90 hyperacetylation, and caspase-dependent Bcr-Abl degradation.MRLB-223 mediates p53-independent tumor cell death, with activity suppressed by Bcl-2 overexpression, and kills Bcr-Abl-expressing myeloid cells.MRLB-223 exerts effects in mice bearing Eμ-myc lymphomas.MRLB-223 can be used for the research of Eμ-myc lymphoma.

For research use only. We do not sell to patients.

MRLB-223

MRLB-223 Chemical Structure

CAS No. : 937727-03-2

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

MRLB-223 Related Antibodies

Top Publications Citing Use of Products

View All HDAC Isoform Specific Products:

View All Isoforms
HDAC HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 HDAC11 HD1 HD2

View All Bcr-Abl Isoform Specific Products:

View All Isoforms
Abl Bcr-Abl

View All HSP Isoform Specific Products:

View All Isoforms
HSP40 HSP70 HSP90 HSP105 HSF1 HSP HSPA5

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

MRLB-223 is a preferential HDAC1 and HDAC2 inhibitor with activity against tumor cells.MRLB-223 induces histone hyperacetylation, intrinsic apoptotic pathway activation, tumor cell apoptosis, Hsp90 hyperacetylation, and caspase-dependent Bcr-Abl degradation.MRLB-223 mediates p53-independent tumor cell death, with activity suppressed by Bcl-2 overexpression, and kills Bcr-Abl-expressing myeloid cells.MRLB-223 exerts effects in mice bearing Eμ-myc lymphomas.MRLB-223 can be used for the research of Eμ-myc lymphoma[1].

IC50 & Target

HDAC1

 

HDAC2

 

HSP90

 

Cellular Effect
Cell Line Type Value Description References
HCT-116 GI50
97 nM
Compound: 2
Growth inhibition of human HCT116 cells after 96 hrs
Growth inhibition of human HCT116 cells after 96 hrs
[PMID: 24900838]
HCT-116 IC50
400 nM
Compound: 2
Inhibition of HDAC in human HCT116 cells assessed as plasma drug level causing increase in H2BK5 acetylation after 24 hrs by ELISA
Inhibition of HDAC in human HCT116 cells assessed as plasma drug level causing increase in H2BK5 acetylation after 24 hrs by ELISA
[PMID: 24900838]
HEK293 IC50
>30 μM
Compound: 2
Inhibition of human ERG expressed in HEK cells by voltage clamp assay
Inhibition of human ERG expressed in HEK cells by voltage clamp assay
[PMID: 24900838]
HEL GI50
120 nM
Compound: 2
Growth inhibition of HEL cells after 96 hrs
Growth inhibition of HEL cells after 96 hrs
[PMID: 24900838]
Jurkat GI50
110 nM
Compound: 2
Growth inhibition of human Jurkat cells after 96 hrs
Growth inhibition of human Jurkat cells after 96 hrs
[PMID: 24900838]
Sf9 IC50
45 nM
Compound: 2
Inhibition of FLAG-tagged full-length human recombinant HDAC2 expressed in baculovirus infected Sf9 cells using acetyl-lysine containing peptide as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by fluorescence as
Inhibition of FLAG-tagged full-length human recombinant HDAC2 expressed in baculovirus infected Sf9 cells using acetyl-lysine containing peptide as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by fluorescence as
[PMID: 24900838]
In Vitro

MRLB-223 (0.2-10 μM; 24-48 h) induces concentration-dependent apoptosis in Eμ-myc lymphoma cells via the intrinsic apoptotic pathway with delayed kinetics, with an IC70 of 5 μM at 24 hours and 0.5 μM at 48 hours[1].
MRLB-223 (0-12 μM; 24 h) induces concentration-dependent apoptosis in Eμ-myc and Eμ-myc/p53-/- lymphoma cells independently of p53, while overexpression of Bcl-2 blocks this apoptotic effect[1].
MRLB-223 (0-30 μM; 24-72 h) induces concentration-dependent cell death in FDCP-1 mouse myeloid cells with delayed kinetics, requiring longer incubation times for maximal effect[1].
MRLB-223 (0-26 μM; 72 h) induces concentration-dependent cell death in FDCP-1/Bcr-Abl and FDCP-1/Bcr-AblT315I cells with delayed kinetics, and Bcr-Abl degradation occurs as a downstream consequence of caspase-mediated apoptosis[1].
MRLB-223 (10 μM; 24 h) induces hyperacetylation of Hsp90 in FDCP-1/Bcr-Abl cells despite lacking activity against HDAC6[1].
MRLB-223 (0-16 μM; 72 h) induces concentration-dependent cell death in FDCP-1/Bcr-Abl cells, and knockdown of HDAC6 does not enhance this apoptotic effect[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

MRLB-223 Related Antibodies

Cell Viability Assay[1]

Cell Line: Eμ-myc, Eμ-myc/p53-/-, and Eμ-myc/Bcl-2 lymphoma cells
Concentration: 0-12 μM
Incubation Time: 24 h
Result: Induced concentration-dependent PI uptake in Eμ-myc and Eμ-myc/p53-/- cells, with both cell lines showing similar sensitivity.
Suppressed MRLB-223-mediated tumor cell death was observed when Bcl-2 was overexpressed.

Cell Viability Assay[1]

Cell Line: FDCP-1/Bcr-Abl and FDCP-1/Bcr-Abl(T315I) mouse myeloid cells
Concentration: 0-26 μM (72 h PI uptake assay); 5, 10 μM (48 h Bcr-Abl degradation assay)
Incubation Time: 72 h (PI uptake assay); 48 h (Bcr-Abl degradation assay)
Result: Induced concentration-dependent PI uptake in FDCP-1/Bcr-Abl and FDCP-1/Bcr-Abl(T315I) cells at 72 hours, with both cell lines showing equivalent sensitivity.
Induced Bcr-Abl degradation concomitant with apoptosis in cells treated with 5 or 10 μM for 48 hours.
Suppressed apoptosis and maintained Bcr-Abl expression when co-treated with the caspase inhibitor Q-VD-OPh for 48 hours.
In Vivo

MRLB-223 (15 mg/kg; i.p.) exerts antitumor activity in mice bearing Eμ-myc lymphoma, extending the median survival to 42 days, but its histone hyperacetylation and antitumor kinetics are delayed compared with broad-spectrum HDAC inhibitors[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 (6- to 8-week-old; injected intravenously with 5×105 Eμ-myc lymphoma cells)[1]
Dosage: 15 mg/kg (therapy studies; in vivo apoptosis assays; FDG-PET analysis)
Administration: i.p.; daily, continuous (therapy studies); single dose (in vivo apoptosis assays; FDG-PET analysis)
Result: Reduced average peripheral white blood cell counts to 23.9×103/μL by day 21 and 33.8×103/μL by day 35 (vehicle controls reached 39.2×103/μL by day 21).
Increased median mouse survival to 42 days (vehicle controls had 33 days).
Induced delayed histone H3 and H4 hyperacetylation in lymphoma cells, with minimal acetylation at 2 hours post-dose and gradual increases over time.
Showed no reduction in lymph node FDG uptake at 4 hours post-dose, but a decrease was observed by 48 hours post-dose.
Molecular Weight

449.53

Formula

C23H23N5O3S
CAS No.
SMILES

O=C1OC2(CCN(CC2)C3=NC=C(C(NC4=C(N)C=CC(C5=CC=CS5)=C4)=O)C=C3)CN1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

MRLB-223 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

MRLB-223937727-03-2MRLB223MRLB 223HDACApoptosisBcr-AblHSPHistone deacetylasesHeat shock proteinstumor cell apoptosisFDCP-1 mouse myeloid cellsp53histone hyperacetylationHsp90 hyperacetylationEμ-myc lymphomasHDAC1intrinsic apoptotic pathwayHDAC2Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
MRLB-223
Cat. No.:
HY-124792
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.